在COVID-19之后治疗肺纤维化的药理方法
Stefan Lassan1, Tomas Tesar2, Jana Tisonova3
1Department of Pneumology, Phthisiology and Functional Diagnostics, Slovak Medical University and Bratislava University Hospital, Bratislava, Slovakia.
Frontiers in pharmacology
|July 3, 2023
概括
后COVID-19肺纤维化在幸存者中越来越令人担忧,导致慢性呼吸系统问题. 目前的治疗方法包括重新使用的药物,如皮质类固醇和抗纤维素药物,但需要更多的研究.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- COVID-19已导致全球显著的发病率和死亡率.
- 预计将有越来越多的COVID-19后续病例,包括肺纤维化.
- 严重的肺损伤可能会在易受感染的个体中发展为间歇性肺干扰.
研究的目的:
- 为提供COVID-19后肺纤维化病的概述.
- 专注于这种情况的潜在药理治疗选择.
主要方法:
- 讨论流行病学,病理生物学机制和风险因素.
- 审查当前和研究中的药物治疗方法.
- 对治疗方案的正在进行和已完成的临床试验的分析.
主要成果:
- 一些药物治疗方法正在使用,包括抗纤维菌药物,皮质类固醇和免疫抑制剂.
- 重用和新型化合物正在调查中.
- 目前,COVID-19后肺纤维化治疗的临床试验结果存在差异.
结论:
- 后COVID-19肺纤维化导致幸存者的慢性呼吸道问题.
- 现有的治疗方法主要是使用重新设计的药物,如皮质类固醇,免疫抑制剂和抗纤维素药物.
- 丁丁达尼布和皮尔芬尼显示出有希望的结果,但需要进一步的研究来优化它们的使用,以防止肺损伤的进展.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
209
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
209
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
218
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
218
COPD: Management Using Bronchodilators and Corticosteroids
250
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
250
Chronic Obstructive Pulmonary Disease-V: Management
2.6K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Smoking Cessation
2.6K
Drugs Used in Lower Respiratory Disorders: Overview
500
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
500
Pulmonary Hypertension: Classification and Pathogenesis
231
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
231


